ASOs, for instance, have progressed to early clinical evaluation, with ION251 (targeting IRF4) completing a Phase 1 trial in relapsed/refractory MM (RRMM) to assess safety and tolerability [360], building on preclinical data showing reductions in MM cell viability and MYC downregulation, while older candidates like Oblimersen (G3139, targeting BCL2) demonstrated encouraging responses in Phase 2 studies for relapsed MM when combined with dexamethasone and thalidomide [361]. Here, BCL2 is linked to Miyoshi myopathy.